ID
37646
Description
Study ID: 104864/612 Clinical Study ID: 104864/612 Study Title: A Prospective, Open Label Phase II Study to Evaluate the Efficacy and Safety of Topotecan (HycamtinTM) in Combination with Carboplatin as First-line Chemotherapy in Patients with Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: HycamtinTM Study Indication: Ovarian Cancer
Mots-clés
Versions (1)
- 13/08/2019 13/08/2019 -
Détendeur de droits
GlaxoSmithKline
Téléchargé le
13 août 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Topotecan (HycamtinTM) with Carboplatin as First-Line Chemotherapy in Patients with Ovarian Cancer; 104864/612
Prior to Second Cycle
- StudyEvent: ODM
Description
Computed tomography
Alias
- UMLS CUI-1
- C0040405
Description
X-Ray Computed Tomography, Performed
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0040405
- UMLS CUI [1,2]
- C0884358
Description
X-Ray Computed Tomography, Changed status
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0040405
- UMLS CUI [1,2]
- C0443172
Description
X-Ray Computed Tomography, Finding
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0040405
- UMLS CUI [1,2]
- C0243095
Description
X-Ray Computed Tomography, Date in time
Type de données
date
Alias
- UMLS CUI [1,1]
- C0040405
- UMLS CUI [1,2]
- C0011008
Description
Assessment of response
Alias
- UMLS CUI-1
- C0521982
- UMLS CUI-2
- C0220825
Description
Response to treatment, Evaluation, Performed
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0521982
- UMLS CUI [1,2]
- C0220825
- UMLS CUI [1,3]
- C0884358
Description
Response to treatment, Evaluation
Type de données
text
Alias
- UMLS CUI [1,1]
- C0521982
- UMLS CUI [1,2]
- C0220825
- UMLS CUI [1,3]
- C0884358
Description
Response to treatment, Evaluation Method
Type de données
text
Alias
- UMLS CUI [1,1]
- C0521982
- UMLS CUI [1,2]
- C2911685
Description
Response to treatment, Evaluation, Date in time
Type de données
date
Alias
- UMLS CUI [1,1]
- C0521982
- UMLS CUI [1,2]
- C0220825
- UMLS CUI [1,3]
- C0011008
Description
Response to treatment, Evaluation, Malignant Neoplasms
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0521982
- UMLS CUI [1,2]
- C0220825
- UMLS CUI [1,3]
- C0006826
Description
Serious adverse events
Alias
- UMLS CUI-1
- C1519255
Description
Status of the study
Alias
- UMLS CUI-1
- C0008976
- UMLS CUI-2
- C0449438
Similar models
Prior to Second Cycle
- StudyEvent: ODM
C0884358 (UMLS CUI [1,2])
C0443172 (UMLS CUI [1,2])
C0243095 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0220825 (UMLS CUI-2)
C0220825 (UMLS CUI [1,2])
C0884358 (UMLS CUI [1,3])
C0220825 (UMLS CUI [1,2])
C0884358 (UMLS CUI [1,3])
C2911685 (UMLS CUI [1,2])
C0220825 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0220825 (UMLS CUI [1,2])
C0006826 (UMLS CUI [1,3])
C0008976 (UMLS CUI [1,2])